David Rafei-Shamsabadi

8PUBLICATIONS
36CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursTumour immunologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 23, 2026
Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial.

|Jan 26, 2024
Epidermolysis-Bullosa-Associated Squamous Cell Carcinomas Support an Immunosuppressive Tumor Microenvironment: Prospects for Immunotherapy.

David Rafei-Shamsabadi, Lena Scholten, Sisi Lu

|Feb 15, 2022
Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy.

David Rafei-Shamsabadi, Saskia Lehr, Max Behrens

|Oct 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.

Ulrike Leiter, Carmen Loquai, Lydia Reinhardt

|Mar 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.

Teresa Amaral, Felix Kiecker, Sarah Schaefer

|Aug 19, 2019
Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone.

David Rafei-Shamsabadi, Saskia Lehr, Dagmar von Bubnoff

Pageof 2

Frequent Collaborators

4 joint publications

Frank Meiss

2 joint publications

Selma Ugurel

1 joint publications

A Schwieger-Briel

1 joint publications

H Schumann